KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Net Margin (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Net Margin data on record, last reported at 37.34% in Q4 2025.

  • For Q4 2025, Net Margin rose 599.0% year-over-year to 37.34%; the TTM value through Dec 2025 reached 32.94%, up 3780.0%, while the annual FY2025 figure was 32.94%, 3780.0% up from the prior year.
  • Net Margin reached 37.34% in Q4 2025 per VRTX's latest filing, up from 35.2% in the prior quarter.
  • Across five years, Net Margin topped out at 42.94% in Q3 2021 and bottomed at 135.83% in Q2 2024.
  • Average Net Margin over 5 years is 26.08%, with a median of 36.82% recorded in 2022.
  • Peak YoY movement for Net Margin: tumbled -17256bps in 2024, then skyrocketed 17067bps in 2025.
  • A 5-year view of Net Margin shows it stood at 37.16% in 2021, then fell by -4bps to 35.56% in 2022, then grew by 8bps to 38.48% in 2023, then fell by -19bps to 31.35% in 2024, then grew by 19bps to 37.34% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 37.34% in Q4 2025, 35.2% in Q3 2025, and 34.84% in Q2 2025.